Keros Therapeutics (KROS)
(Delayed Data from NSDQ)
$57.86 USD
+3.67 (6.77%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $57.82 -0.04 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Keros Therapeutics, Inc. (KROS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$86.75 | $105.00 | $60.00 | 60.08% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Keros Therapeutics, Inc. comes to $86.75. The forecasts range from a low of $60.00 to a high of $105.00. The average price target represents an increase of 60.08% from the last closing price of $54.19.
Analyst Price Targets (8 )
Broker Rating
Keros Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, 10 are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 10 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/27/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
3/6/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
2/29/2024 | Wedbush Securities | Andreas Argyrides | Strong Buy | Strong Buy |
2/21/2024 | William Blair | Matt Phipps | Not Available | Strong Buy |
1/19/2024 | BTIG | Julian Harrison | Strong Buy | Strong Buy |
10/22/2023 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 10 |
Average Target Price | $86.75 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -1.31 |